GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alvotech (OISE:ALVO) » Definitions » Current Deferred Revenue

Alvotech (OISE:ALVO) Current Deferred Revenue : kr6,358 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Alvotech Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Alvotech's current deferred revenue for the quarter that ended in Mar. 2024 was kr6,358 Mil.

Alvotech Current Deferred Revenue Historical Data

The historical data trend for Alvotech's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alvotech Current Deferred Revenue Chart

Alvotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
- 1,950.70 4,081.18 5,073.98 8,134.72

Alvotech Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,415.23 8,106.55 7,342.46 8,134.72 6,358.18

Alvotech Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Alvotech's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alvotech (OISE:ALVO) Business Description

Traded in Other Exchanges
Address
9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.